A Phase I/II Study Investigating the Combination of RAD001 and Rituximab in Patients With Non-Hodgkin's Lymphomas

Trial Profile

A Phase I/II Study Investigating the Combination of RAD001 and Rituximab in Patients With Non-Hodgkin's Lymphomas

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2016

At a glance

  • Drugs Everolimus (Primary) ; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RAD001-R
  • Most Recent Events

    • 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 10 Apr 2012 New trial record
    • 29 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top